Valproic Acid Solution
NDC Package 70518-3805-2

11-digit billing NDC: 70518380502

Package Information

Valproic Acid solution is valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)] .  Valproic acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)]. This formulation utilizes a solution delivery system. Marketed by Remedyrepack Inc., this product is identified by NDC 70518-3805 and is authorized under FDA application ANDA075379.

Identification & Billing

NDC Package Code
70518-3805-2
Package Description
10 CUP, UNIT-DOSE in 1 BOX / 10 mL in 1 CUP, UNIT-DOSE (70518-3805-3)
Product Code
11-Digit Billing Format
70518380502
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Valproic Acid
Non-Proprietary Name
Valproic Acid
Substance Name
Valproic Acid
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Valproic acid should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)] .  Valproic acid is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)] . Valproic acid is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)] . Valproic acid is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)] . For use in prophylaxis of migraine headaches: Valproic acid is contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4)and Use in Specific Populations (8.1)] .

Regulatory & Marketing

Labeler Name
Remedyrepack Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA075379
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-25-2023
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70518-3805). Click a package code to view its specific billing and regulatory data.

10 CUP, UNIT-DOSE in 1 BOX / 5 mL in 1 CUP, UNIT-DOSE (70518-3805-1)

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70518-3805-2 identifies a specific commercial package of 10 cup, unit-dose in 1 box / 10 ml in 1 cup, unit-dose (70518-3805-3) of Valproic Acid, a human prescription drug labeled by Remedyrepack Inc.. This solution is formulated for oral use and contains valproic acid as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Remedyrepack Inc. on July 25, 2023. The current certification is valid through December 31, 2027.

How is this Remedyrepack Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70518380502. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70518-3805-2
11-Digit CMS (5-4-2)
70518-3805-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.